Thus, it will be important to determine whether CML cells are more sensitive to GLI inhibition compared to SMO inhibition, as this would suggest that the HH pathway is activated in a SMO-independent manner and would comprise an alternative route for overcoming resistance to SMO inhibitors. This evidence concerns the gene SMO and chronic myelogenous leukemia, BCR-ABL1 positive.